Research ArticleCancer

Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade

See allHide authors and affiliations

Science Translational Medicine  09 Sep 2020:
Vol. 12, Issue 560, eaax2282
DOI: 10.1126/scitranslmed.aax2282

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

All roads lead to antitumor immunity

Immune checkpoint blockade immunotherapy for cancer has been achieving increasing prominence in recent years, but, unfortunately, it still only works for a subset of patients and tumor types. Wang et al. found that higher expression of lysine demethylase KDM5A in tumors correlates with their responses to immune checkpoint inhibition. The authors then found a way to take advantage of this mechanism using a compound that increased both KDM5A and a key immune checkpoint protein. At the same time, this compound also activated Toll-like receptor signaling, further stimulating antitumor immunity in multiple mouse models.

View Full Text

Stay Connected to Science Translational Medicine